Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Microenvironment
Published in: Cancer Microenvironment 1/2010

01-12-2010 | Review Paper

Cancer–Stromal Interactions in Scirrhous Gastric Carcinoma

Authors: Masakazu Yashiro, Kosei Hirakawa

Published in: Cancer Microenvironment | Issue 1/2010

Login to get access

Abstract

Fibroblasts play an important role in the progression, growth and spread of gastric cancers. Cancer–stroma interactions have been especially evident in the scirrhous type of gastric carcinoma. Fibroblasts are associated with the cancer progression at the primary and metastatic site. The proliferative and invasive ability of scirrhous gastric cancer cells are closely associated with the growth factors produced by organ-specific fibroblasts. Fibroblasts are therefore a key determinant in the malignant progression of gastric cancer and represent an important target for cancer therapies.
Literature
1.
2.
Japanese Gastric Cancer A (1998) Japanese classification of gastric carcinoma—2nd English Edition. Gastric Cancer 1(1):10–24CrossRef
3.
Ikeguchi M, Miyake T, Matsunaga T et al (2009) Recent results of therapy for scirrhous gastric cancer. Surg Today 39(4):290–294CrossRefPubMed
4.
Otsuji E, Kuriu Y, Okamoto K et al (2004) Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am J Surg 188(3):327–332CrossRefPubMed
5.
Tahara E (2004) Genetic pathways of two types of gastric cancer. IARC Sci Publ 157:327–349PubMed
6.
Yashiro M, Chung YS, Kubo T et al (1996) Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts. Br J Cancer 74(7):1096–1103PubMedCrossRef
7.
Mueller MM, Fusenig NE (2004) Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4(11):839–849CrossRefPubMed
8.
Yashiro M, Chung YS, Sowa M (1994) Role of orthotopic fibroblasts in the development of scirrhous gastric carcinoma. Jpn J Cancer Res 85(9):883–886PubMed
9.
Nakazawa K, Yashiro M, Hirakawa K (2003) Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res 63(24):8848–8852PubMed
10.
Shaoul R, Eliahu L, Sher I et al (2006) Elevated expression of FGF7 protein is common in human gastric diseases. Biochem Biophys Res Commun 350(4):825–833CrossRefPubMed
11.
Katoh M, Katoh M (2006) FGF signaling network in the gastrointestinal tract (review). Int J Oncol 29(1):163–168PubMed
12.
Katoh M (2008) Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 33(2):233–237PubMed
13.
Takemura S, Yashiro M, Sunami T et al (2004) Novel models for human scirrhous gastric carcinoma in vivo. Cancer science 95(11):893–900CrossRefPubMed
14.
Yashiro M, Chung YS, Nishimura S et al (1996) Fibrosis in the peritoneum induced by scirrhous gastric cancer cells may act as “soil” for peritoneal dissemination. Cancer 77(8 Suppl):1668–1675PubMed
15.
Ronnov-Jessen L, Petersen OW, Bissell MJ (1996) Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 76(1):69–125PubMed
16.
Tahara E (2008) Abnormal growth factor/cytokine network in gastric cancer. Cancer Microenviron 1(1):85–91CrossRefPubMed
17.
Elenbaas B, Weinberg RA (2001) Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 264(1):169–184CrossRefPubMed
18.
Mahara K, Kato J, Terui T et al (1994) Transforming growth factor beta 1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue. Br J Cancer 69(4):777–783PubMedCrossRef
19.
Yoshida K, Yokozaki H, Niimoto M et al (1989) Expression of TGF-beta and procollagen type I and type III in human gastric carcinomas. Int J Cancer 44(3):394–398CrossRefPubMed
20.
Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9(4):239–252CrossRefPubMed
21.
Cat B, Stuhlmann D, Steinbrenner H et al (2006) Enhancement of tumor invasion depends on transdifferentiation of skin fibroblasts mediated by reactive oxygen species. J Cell Sci 119(Pt 13):2727–2738CrossRefPubMed
22.
De Wever O, Demetter P, Mareel M et al (2008) Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123(10):2229–2238CrossRefPubMed
23.
De Wever O, Mareel M (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200(4):429–447CrossRefPubMed
24.
Inoue T, Chung YS, Yashiro M et al (1997) Transforming growth factor-beta and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res 88(2):152–159PubMed
25.
George SJ, Johnson JL, Smith MA et al (2005) Transforming growth factor-beta is activated by plasmin and inhibits smooth muscle cell death in human saphenous vein. J Vasc Res 42(3):247–254CrossRefPubMed
26.
Duffy MJ, Maguire TM, McDermott EW et al (1999) Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71(2):130–135CrossRefPubMed
27.
Herszenyi L, Plebani M, Carraro P et al (2000) Proteases in gastrointestinal neoplastic diseases. Clin Chim Acta 291(2):171–187CrossRefPubMed
28.
Zeisberg EM, Potenta S, Xie L et al (2007) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67(21):10123–10128CrossRefPubMed
29.
Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454CrossRefPubMed
30.
Kalluri R, Neilson EG (2003) Epithelial–mesenchymal transition and its implications for fibrosis. J Clin Invest 112(12):1776–1784PubMed
31.
Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3(11):807–821CrossRefPubMed
32.
Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541–573CrossRefPubMed
33.
Boire A, Covic L, Agarwal A et al (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120(3):303–313CrossRefPubMed
34.
Yashiro M, Chung YS, Sowa M (1997) Tranilast (N-(3,4-dimethoxycinnamoyl) anthranilic acid) down-regulates the growth of scirrhous gastric cancer. Anticancer Res 17(2A):895–900PubMed
35.
Humar B, Guilford P (2009) Hereditary diffuse gastric cancer: a manifestation of lost cell polarity. Cancer science 100(7):1151–1157CrossRefPubMed
36.
Yashiro M, Nishioka N, Hirakawa K (2006) Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur J Cancer 42(14):2397–2403CrossRefPubMed
37.
Nishioka N, Yashiro M, Inoue T et al (2001) A candidate tumor suppressor locus for scirrhous gastric cancer at chromosome 18q 12.2. Int J Oncol 18(2):317–322PubMed
38.
Nishimura S, Chung YS, Yashiro M et al (1996) CD44H plays an important role in peritoneal dissemination of scirrhous gastric cancer cells. Jpn J Cancer Res 87(12):1235–1244PubMed
39.
Koyama T, Yashiro M, Inoue T et al (2000) TGF-beta1 secreted by gastric fibroblasts up-regulates CD44H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. Int J Oncol 16(2):355–362PubMed
40.
Nishimura S, Chung YS, Yashiro M et al (1996) Role of alpha 2 beta 1- and alpha 3 beta 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma. Br J Cancer 74(9):1406–1412PubMedCrossRef
41.
Kizaka-Kondoh S, Itasaka S, Zeng L et al (2009) Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 15(10):3433–3441CrossRefPubMed
42.
Graf J, Iwamoto Y, Sasaki M et al (1987) Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 48(6):989–996CrossRefPubMed
43.
Akiyama SK, Yamada SS, Chen WT et al (1989) Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization. J Cell Biol 109(2):863–875CrossRefPubMed
44.
Iwamoto Y, Robey FA, Graf J et al (1987) YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 238(4830):1132–1134CrossRefPubMed
45.
Matsuoka T, Hirakawa K, Chung YS et al (1998) Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer. Clin Exp Metastasis 16(4):381–388CrossRefPubMed
46.
Yashiro M, Chung YS, Nishimura S et al (1996) Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin Exp Metastasis 14(1):43–54CrossRefPubMed
47.
Paget S (1989) The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8(2):98–101PubMed
48.
Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458CrossRefPubMed
49.
Psaila B, Lyden D (2009) The metastatic niche: adapting the foreign soil. Nat Rev Cancer 9(4):285–293CrossRefPubMed
50.
Nishimura S, Hirakawa-Chung KY, Yashiro M et al (1998) TGF-beta1 produced by gastric cancer cells affects mesothelial cell morphology in peritoneal dissemination. Int J Oncol 12(4):847–851PubMed
51.
Yashiro M, Chung YS, Inoue T et al (1996) Hepatocyte growth factor (HGF) produced by peritoneal fibroblasts may affect mesothelial cell morphology and promote peritoneal dissemination. Int J Cancer 67(2):289–293CrossRefPubMed
52.
Schor SL, Schor AM, Grey AM et al (1988) Foetal and cancer patient fibroblasts produce an autocrine migration-stimulating factor not made by normal adult cells. J Cell Sci 90(Pt 3):391–399PubMed
53.
Durning P, Schor SL, Sellwood RA (1984) Fibroblasts from patients with breast cancer show abnormal migratory behaviour in vitro. Lancet 2(8408):890–892CrossRefPubMed
54.
Olumi AF, Grossfeld GD, Hayward SW et al (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59(19):5002–5011PubMed
55.
Lewis MP, Lygoe KA, Nystrom ML et al (2004) Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer 90(4):822–832CrossRefPubMed
56.
Liu Y, Yoshimura K, Yamaguchi N et al (2003) Causation of Borrmann type 4 gastric cancer: heritable factors or environmental factors? Gastric Cancer 6(1):17–23CrossRefPubMed
57.
Samel S, Singal A, Becker H et al (2000) Problems with intraoperative hyperthermic peritoneal chemotherapy for advanced gastric cancer. Eur J Surg Oncol 26(3):222–226CrossRefPubMed
58.
Prud’homme GJ (2007) Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 87(11):1077–1091CrossRefPubMed
59.
Murahashi K, Yashiro M, Inoue T et al (1998) Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer. Int J Oncol 13(6):1235–1240PubMed
60.
Yashiro M, Murahashi K, Matsuoka T et al (2003) Tranilast (N-3,4-dimethoxycinamoyl anthranilic acid): a novel inhibitor of invasion-stimulating interaction between gastric cancer cells and orthotopic fibroblasts. Anticancer Res 23(5A):3899–3904PubMed
61.
Iwata C, Kano MR, Komuro A et al (2007) Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 67(21):10181–10189CrossRefPubMed
62.
Tendo M, Yashiro M, Nakazawa K et al (2005) Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells. Cancer science 96(7):451–455CrossRefPubMed
63.
Sonoshita M, Takaku K, Oshima M et al (2002) Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 62(23):6846–6849PubMed
64.
Oshima M, Dinchuk JE, Kargman SL et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5):803–809CrossRefPubMed
65.
Williams CS, Tsujii M, Reese J et al (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105(11):1589–1594CrossRefPubMed
66.
Sawaoka H, Kawano S, Tsuji S et al (1998) Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274(6 Pt 1):G1061–G1067PubMed
67.
Chen WS, Wei SJ, Liu JM et al (2001) Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 91(6):894–899CrossRefPubMed
68.
Tsujii M, Kawano S, Tsuji S et al (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93(5):705–716CrossRefPubMed
69.
Kamei D, Murakami M, Nakatani Y et al (2003) Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 278(21):19396–19405CrossRefPubMed
70.
Tendo M, Yashiro M, Nakazawa K et al (2006) A synergic inhibitory-effect of combination with selective cyclooxygenase-2 inhibitor and S-1 on the peritoneal metastasis for scirrhous gastric cancer cells. Cancer Lett 244(2):247–251CrossRefPubMed
71.
Yashiro M, Nakazawa K, Tendo M et al (2007) Selective cyclooxygenase-2 inhibitor downregulates the paracrine epithelial–mesenchymal interactions of growth in scirrhous gastric carcinoma. Int J Cancer 120(3):686–693CrossRefPubMed
72.
Hattori Y, Itoh H, Uchino S et al (1996) Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 2(8):1373–1381PubMed
73.
Toyokawa T, Yashiro M, Hirakawa K (2009) Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol Rep 21(4):875–880PubMed
74.
Hattori Y, Odagiri H, Nakatani H et al (1990) K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci U S A 87(15):5983–5987CrossRefPubMed
75.
Katoh M, Hattori Y, Sasaki H et al (1992) K-sam gene encodes secreted as well as transmembrane receptor tyrosine kinase. Proc Natl Acad Sci U S A 89(7):2960–2964CrossRefPubMed
76.
Shimizu T, Fujiwara Y, Osawa T et al (2004) Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors. Bioorg Med Chem Lett 14(4):875–879CrossRefPubMed
77.
Nakamura K, Yashiro M, Matsuoka T et al (2006) A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 131(5):1530–1541CrossRefPubMed
78.
Yashiro M, Shinto O, Nakamura K et al (2009) Synergistic anti-tumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer 126(4):1004–1016
79.
Yashiro M, Shinto O, Nakamura K et al (2009) Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model. Br J Cancer 101(7):1100–1106CrossRefPubMed
80.
Kawajiri H, Yashiro M, Shinto O et al (2008) A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res 14(9):2850–2860CrossRefPubMed
81.
Bierie B, Moses HL (2006) Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6(7):506–520CrossRefPubMed
82.
Akhurst RJ (2002) TGF-beta antagonists: why suppress a tumor suppressor? J Clin Invest 109(12):1533–1536PubMed
Metadata
Title
Cancer–Stromal Interactions in Scirrhous Gastric Carcinoma
Authors
Masakazu Yashiro
Kosei Hirakawa
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Cancer Microenvironment / Issue 1/2010
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI
https://doi.org/10.1007/s12307-010-0036-5

Other articles of this Issue 1/2010

Cancer Microenvironment 1/2010 Go to the issue

Review Paper

T Cells and Stromal Fibroblasts in Human Tumor Microenvironments Represent Potential Therapeutic Targets

Review Paper

Stromal Fibroblasts in Digestive Cancer

Editorial

The 5th International Conference on Tumor Microenvironment: Progression, Therapy and Prevention Versailles, France, October 20–24, 2009

Review Paper

The Tumor Microenvironment in Colorectal Carcinogenesis

Review Paper

The Hemopoietic Stem Cell Niche Versus the Microenvironment of the Multiple Myeloma-Tumor Initiating Cell

Original Paper

Selectins as Mediators of Lung Metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits